Podcast appearances and mentions of roger mcintyre

In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Identify common potentially unsafe drug combinations that may be considered in treatment-resistant cases Evaluate the risks and benefits of prescribing potentially unsafe drug combinations for treatment-resistant patients, considering factors such as efficacy, adverse effects, and patient-specific characteristics Develop strategies to monitor and manage patients prescribed potentially unsafe drug combinations Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour. Released: March 26, 2025*   Expiration: March 25, 2028 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-01 Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until March 25, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, and cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education take responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, ON, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, NEI and HMP planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, and Steven S. Simring, MD, MPH. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Join Drs. Andy Cutler and Roger McIntyre as they discuss the most significant advancements in psychopharmacology over the past year. Their conversation highlights groundbreaking developments and innovations in the field of psychiatry.  Resources  This Month in Psychopharmacology  Never miss an episode!

This episode includes extended Q&A sessions that address your unanswered questions from the following presentations delivered at the 2024 Congress in Colorado Springs, Colorado:  (00:23) Panic On the Playground! Managing Social Anxiety in Pediatric Patients by Katherine Dahlsgaard, PhD, ABPP and Jeffrey Strawn, MD (Q&A with Dr. Dahlsgaard)   (15:12) Inflammatory Remarks: Our Evolving Understanding of the Role of Inflammation in Mental Health by Roger McIntyre, MD, FRCPC and Vladimir Maletic, MD, MS (Q&A with Dr. McIntyre)   (35:33) Wake Me Up Before You Go-Go: Strategies for Improving Sleep-Wake Issues by Thomas Schwartz, MD   (51:32) Beyond the Blues: Risk, Recognition, and Relief from Perinatal Mood and Anxiety Disorders by Lisa Tremayne, RN, PMH-C, CBC (lisa.tremayne@rwjbh.org)  Never miss an episode!

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder Develop patient-centered treatment plans that incorporate current evidence and individual patient factors Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 01, 2024*   Expiration: October 31, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, Ontario, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/modeling-activity-quality-conversations-with-patients-about-suboptimal-management-of-ptsd-symptoms-and-emerging-treatment-options/28647/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/prevalence-and-burden-of-ptsd-in-women-focus-on-factors-that-affect-patient-presentation-such-as-race-risk-factors-stigma-and-other-drivers/28620/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pathophysiology-and-pharmacologic-rationale-of-emerging-agents-for-the-treatment-of-ptsd/28626/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/limitations-of-current-treatments-fda-approved-and-off-label-approaches/28625/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/inconsistent-outcomes-how-ignoring-guidelines-leads-to-unpredictable-results/28624/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/conversations-with-patients-about-ptsd-screening-and-referral/28623/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/proactively-uncovering-potential-traumatic-experiences-linked-to-patient-psychiatric-symptoms-in-women/28622/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/profile-and-role-of-emerging-treatment-options-moa-safety-and-efficacy-and-identifying-the-patients-who-may-benefit/28627/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-stage-unmet-needs-in-the-treatment-of-women-with-ptsd/28618/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/role-of-pcp-ob-gyn-with-women-at-risk-for-ptsd-recognition-screening-and-referral/28621/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

Tara takes the opportunity to join Pastor James Lynch and Roger and Kathy McIntyre for a heartfelt discussion about Kathy's journey through cancer. They explore her hopeful outlook and emphasize the vital role of their church family in providing support and connection during this challenging time.

Drs. Roger McIntyre and Greg Mattingly share their insights into the role of emerging and novel mechanisms of action for potential treatments of schizophrenia, particularly those addressing the negative and cognitive symptoms.

Dr. Roger McIntyre is a leading expert in the field of mood disorders. Join us for part two of our interview discussing Bipolar Disorder and metabolic implications. Follow Dr. Roger McIntyre on X: ⁠@rogersmcintyre

Join us for our first guest episode! Dr. Roger McIntyre is a leading expert in the field of mood disorders. Today, he will be sharing valuable insight on his extensive clinical experience with Bipolar Disorder. Follow Dr. Roger McIntyre on X: @rogersmcintyre

We looked at this class of weight loss drugs a year ago, and they've only gotten more popular — and more controversial. We're hearing that these kinds of drugs can be tough on your stomach, and that the weight loss comes with worrisome loss of muscle. We've also heard claims that they might increase your risk of suicide. So — should we be freaking out here?? We talk to endocrinologist Dr. Vibha Singhal, neuroscientist Dr. Nora Volkow, and gastroenterologist Dr. Michael Camilleri.   This episode does deal with depression and suicidal thoughts. Here are some crisis hotlines:  United States: US National Suicide Prevention Lifeline Dial 988 (Online chat available); US Crisis Text Line Text “HOME” to 741741 Australia: Lifeline 13 11 14 (Online chat available) Canada: Canadian Association for Suicide Prevention (See link for phone numbers listed by province) United Kingdom: Samaritans 116 123 (UK and ROI) Full list of international hotlines here  Find our transcript here: https://bit.ly/ScienceVsOzempic2Scarier  Chapters: In this episode, we cover: (00:00) What are the fears around these weight loss drugs?  (04:46) Do these drugs melt your muscles? (11:49) Do these drugs increase the risk of suicidal thoughts?  (16:15) Can they really paralyze your stomach? (30:25) Some good news! (33:36) How Did You Find the Bezoar? CREDITS This episode was produced by Rose Rimler, with help from Wendy Zukerman, Meryl Horn, Michelle Dang, and Joel Werner. We're edited by Blythe Terrell. Fact checking by Erica Akiko Howard. Recording assistance from Selena Seay-Reynolds. Mix and sound design by Bobby Lord and Peter Leonard. Music written by Bumi Hidaka, Emma Munger, Peter Leonard, So Wylie and Bobby Lord. Thanks to all of the researchers we spoke to for this episode, including Dr. Kristen Beavers, Dr. Ellen Fallows, Dr. Joseph Henson, Dr. Dimitrios Papamargaritis, Prof. Roger McIntyre, Prof. Russ Waitman, Dr. Sahib Khalsa,, Dr. Travis Masterson, and Dr. Etienne Wang. Thanks also to Bryant Smith and Lori Segal. And special thanks to the listeners on these medications who checked back in with us.    A special thanks to the Zukerman Family and Joseph Lavelle Wilson. Science Vs is a Spotify Studios Original. Listen for free on Spotify or wherever you get your podcasts. Follow us and tap the bell for episode notifications. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada, returns to introduce depressive disorders. We differentiate normal "low mood" from conditions that warrant a psychiatric diagnosis. We discuss historical subtypes of depression and the current DSM specifiers for major depressive disorder. We review epidemiology, discuss the neurophysiology of depressive disorders, and then dive into treatment options.

Dr. Roger McIntyre,  Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada, introduces us to bipolar disorders. We discuss the key clinical features of bipolar disorders, the relationship between bipolar disorders and circadian rhythm, known pathogenesis, and some first line treatment options. We also contextualize the difference between "type I" and "type II" bipolar disorder, and explore the relationship between bipolar disorder and traumatic life experiences. For more: Bipolar Disorders (Lancet Seminar)

GLP1 medications like Wegovy and Ozempic can help with weight loss but may also be able to help with psychiatric symptoms from depression, bipolar disorder, anxiety, and more. But are GLP1s safe in psychiatry, and how do they compare to nutritional interventions like a ketogenic diet to treat mental health disorders? Dr. Roger McIntrye, a world-renowned psychiatrist and researcher, joins Metabolic Mind to discuss the potential roles of GLP1 medications and ketogenic therapy, and how clinicians and patients could consider their use. Expert featured in this episode: Roger McIntyre, MD https://psychiatry.utoronto.ca/faculty/roger-mcintyre Twitter/X: @rogersmcintyre About us: Metabolic Mind™ is a nonprofit initiative incubated by Baszucki Group. Our mission is to provide education and resources in the emerging field of metabolic psychiatry, including ketogenic interventions for mental disorders. Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications. #MetabolicMind #KetoForMentalHealth #MetabolicPsychiatry #BipolarTreatment #KetogenicMetabolicTherapy #NutritionalKetosis#MentalIllness#Bipolar#GLP1#Ozempic#Wegovy#weightloss #AlternativeTreatment

What were some new treatments approved by the FDA? What did we learn about the long-term safety of methylphenidate in childhood ADHD? Are there benefits to long-term maintenance treatment with antidepressants in bipolar disorder? What did we learn about the safety and efficacy of subcutaneous racemic ketamine for treatment-resistant depression and MDMA for PTSD? In this episode, Dr. Andrew Cutler and Dr. Roger McIntyre address these questions and so much more about this past year in psychopharmacology.   Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His work broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.    

What is the role of the 5HT2A receptor in the therapeutic actions of psychedelics? What additional mechanisms may be involved in the therapeutic benefits of classic psychedelics? Is the psychedelic trip necessary for the therapeutic benefit of psychedelics?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry.  Today, Dr. Andy Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl about the current understanding of the neurobiological mechanisms underlying the therapeutic benefits of psychedelics.  Let's listen to Part 2 of our theme: Classic Psychedelics for the Modern Psychopharmacologist.  Subscribe to the NEI Podcast, so that you don't miss another episode!   

In this episode, Dr. Roger McIntyre addresses your unanswered questions from his presentation, Unveiling the Therapeutic Potential: Evidence Supporting the Use of Psychedelics for PTSD, SUD, and Other Indications, at the Pre-Conference Psychedelics Workshop.

In this episode, Dr. Roger McIntyre addresses your unanswered questions from his presentation: The “Mania” Event: Distinguishing Between Treating Bipolar I and Bipolar II.

Dr. Roger McIntyre is the chairman and chief executive officer of Braxia Scientific. Dr. McIntyre is the world's top-ranked depression researcher and has almost 25 years of providing care and conducting research, along with drug discovery and development, for persons with depression and related disorders.He is currently also a professor of psychiatry and pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada.https://braxiascientific.comhttps://psychiatry.utoronto.ca/faculty/roger-mcintyrehttps://www.linkedin.com/in/roger-mcintyre-976bb167?originalSubdomain=ca

In this episode, Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, shed light on the symptom improvement timeline in bipolar depression. This is a topic made more complex when factoring in individual patient characteristics and comorbidities, but the 2 experts have astute insights on how to tailor a management plan based on such factors. They cover symptom management and improvement from a variety of angles, including evaluating improvement in functionality and mood, guidance on follow-up and dose adjustment schedules, the utility of measurement-based care, and—of most importance—how to best communicate with and support a patient while they work towards remission and recovery.Presenters:Joseph F. Goldberg, MDClinical Professor of PsychiatryDepartment of PsychiatryIcahn School of Medicine at Mount SinaiNew York, New YorkRoger McIntyre, MD, FRCPCProfessor of Psychiatry and PharmacologyDepartment of Psychiatry/PharmacologyUniversity of TorontoHead, Mood Disorders Psychopharmacology UnitDepartment of PsychiatryToronto, CanadaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit:https://bit.ly/3ft1rYI

In this episode, we take a look back at Dr. Roger McIntyre's presentation on the treatment spectrum for depression and mania. In this sneak peek, Dr. McIntyre focuses on the current treatments that are available for the bipolar disorder spectrum. He addresses the implications of comorbid substance abuse with respect to pharmacological treatments. He also discusses lifestyle factors that can be preventative against cognitive decline associated with mood disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World's Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

Dr. Roger McIntyre, a professor of Psychiatry and Pharmacology at the University of Toronto

On today's show, ketamine and psilocybin are normally known as party drugs, but we chat with Dr. Roger McIntyre, a professor of psychiatry and pharmacology at the University of Toronto, about how they're being used to treat depression. Plus what will it take for Ukraine to win the war with Russia? We ask John Herbst, a former U.S. ambassador to Ukraine. Also a 110-million-year-old raptor skeleton recently sold for $12 million at auction. We chat with Dr. Jessica M. Theodor, a professor of biological sciences at the University of Calgary, about why these artifacts shouldn't be sold. And we chat with Wanda Bogdane, the director of communications and stakeholder engagement with Banff and Lake Louise Hospitality Association, on the shortage of staff ahead of summer tourist season.

In this episode, Dr. Roger McIntyre addresses your most pressing questions from his presentation: Bipolar Disorder Rainbow: The Spectrum of Treatments for Depression and Mania at the 2022 NEI Synapse.

Ann Rohmer speaks with Dr. Roger McIntyre - Professor of Psychiatry and Pharmacology, University of Toronto about the lifting of the mask mandate; is it too soon? What if you prefer to remain masked? On the anniversary of the WHO declaring COVID19 a pandemic (March 11-2020), Ann Rohmer discusses the Pandemic with York Region's Medical Officer of Health Dr. Barry Pakes. Tina Cortese looks into how Air Canada, Airlink, Project C.U.R.E. and GlobalMedic have joined forces to directly help Ukrainian refugees arriving in Poland and those still in Ukraine. A special humanitarian cargo charter flight, operated by Air Canada onboard a Boeing 787-9 Dreamliner aircraft, will transport medical equipment from Airlink and Project C.U.R.E. including hospital beds, vinyl mattresses and other humanitarian supplies. GlobalMedic will be sending medical supplies, trauma dressings and wound care supplies destined for a hospital in Lviv, Ukraine. The flight will depart Toronto Pearson for Warsaw, Poland, on Wednesday evening, March 9, 2022. Kevin Frankish has details of a recent KPMG poll which finds that nearly half (49 per cent) would buy an EV made by a major technology company (Google, Apple, Amazon, Huawei, Samsung), a trend that automotive executives are already anticipating. Jim Lang is with author Tanvir Bhangoo who's book THE PRO Business Mindset — which hit #1 Amazon Best Seller in multiple categories, and #6 Hot New Release across all Management & Leadership Books. He applied leadership lessons from sports(championship footballer at McMaster), based on what he had learned on the football field, to help organizations adapt and transform amid disruption and chaos. How can principles built from a world of sports apply to leadership in business?

Kelly speaks to Dr. Roger McIntyre, a professor of psychiatry and pharmacology at the University of Toronto.

Braxia Scientific CEO Dr. Roger McIntyre joined Steve Darling from Proactive to share ground-breaking news that the first Health Canada-approved multiple-dose psilocybin clinical trial has commenced with the first patients dosed in November 2021. Dr. McIntyre telling Proactive this is the only Health Canada approved psilocybin trial in Canada that is actively recruiting participants at this time. This trial is being conducted at the Canadian Rapid Treatment Center of Excellence and includes adults with treatment-resistant depression as part of bipolar or unipolar disorder, who have not benefited from multiple conventional treatments.

In this episode, Roger McIntyre, MD, FRCPC, and Sanjay Mathew, MD, discuss choosing the right treatment in bipolar depression. They review patient assessment and differential diagnosis for bipolar depression, describe various screening tools, examine evidence-based pharmacotherapies, consider the role of adjunctive antidepressants, neuromodulation, light therapy, and psychological treatments, and explore future directions in bipolar depression treatment.  Presenters:Sanjay J. Mathew, MDProfessor and Vice Chair for ResearchPsychiatry and Behavioral SciencesBaylor College of MedicineHouston, TexasRoger McIntyre, MD, FRCPCProfessor of Psychiatry and PharmacologyDepartment of Psychiatry/PharmacologyUniversity of TorontoHead, Mood Disorders Psychopharmacology UnitDepartment of PsychiatryToronto, CanadaLink to full program:https://bit.ly/3syJzh2  

CBC reporter Erik White joins us from Sudbury to talk about about the arrival of Starllink, the satellite-based high speed internet serviice; Erica Johnson from CBC's Go Public reports on the predicament of a women who found her self-service storage locker robbed of her cherished - and valuable - belongings; With the new Covid-19 variant Omicron being identified in South Africa, epidemiologists are once again pointing out the inequalities of global vaccine distribution. Brittany Lambert of Oxfam Canada offers her perspective; Local ski resorts are preparing for the season...and hoping to avoid another lockdown this winter. Robert Huter of Mt. St. Louis Moonstone ski resort talks to us about snow conditions and COVID-19 protocols; You may have a robot vacuum cleaner - but Innisfil has snowbots - robots that will clear the sidewalks. We find out more from Nicole Bowman, the town's Director of Operations; According to new data from Statistics Canada more than 10 per cent of Canadians over the age of 15 say they always or often feel lonely. We have reaction to the situation from psychiatrist Roger McIntyre; Last Friday, Riverview Park and Zoo in Peterborough welcomed the general public back for the first time since March 2020. General manager Jim Moloney talks about the reopening.

In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre on best practices for using adjunctive treatment for major depressive disorder. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MDD Learning Objectives: After completing this educational activity, you should be better able to: Discuss earlier identification of partial response to anti-depressants and advantages to implementing augmentation strategies sooner to improve treatment outcomes Increase awareness about evidence-based adjunctive treatments that are FDA-approved for depression Examine the pharmacological profiles of approved adjunctive atypical antipsychotic treatments in terms of how they relate to therapeutic benefits and adverse reactions Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this online live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME/CE Credit Types. The following are being offered for this activity: Nursing (ANCC): 1.0 contact hour Pharmacy (ACPE): 1.0 application-based contact hour Physician (ACCME): 1.0 AMA PRA Category 1 Credit ™ Physician Assistant (AAPA): 1.0 Category 1 CME credit Psychology (APA): 1.0 CE credit Social Work (ASWB-ACE): 1.0 ACE CE credit Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for 1.0 AMA PRA Category 1 Credit ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/National Natural Science Foundation of China Consultant/Advisor: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda Speakers Bureau: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture Support: This activity is supported by an unrestricted educational grant from Otsuka and Lundbeck. Released: October 21, 2021          CE credit expires: October 21, 2024    

From MDMA to ketamine to psychedelics, the drugs we were told in high school that would ruin our lives are now being used to potentially save lives. Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, discusses the growing promise of ketamine therapy to treat severe depression and the shift to cutting edge treatments using other substances such as MDMA and psylocibin from so-called magic mushrooms. See omnystudio.com/listener for privacy information.

Today's guests: Stephanie Carvin, Associate Professor of International Relations at the Norman Paterson School of International Affairs (Carleton University) Dr.Roger McIntyre, Professor of Psychiatry and Pharmacology - University of Toronto Evan Menzies, senior campaign strategist with Crestview Strategy and former director of communications for the United Conservative Party and Wildrose caucus See omnystudio.com/listener for privacy information.

They're portrayed as a mechanism to achieve self-knowledge in the Amazon Prime show, Nine Perfect Strangers. They were the subject of promising clinical trials in the New England Journal of Medicine and Nature Medicine. They fascinate Joe Rogan and Tim Ferriss, and their promise was even the subject of a book by Michael Pollan (How to Change Your Mind). So is the buzz about psychedelics justified? What's the deal with microdosing? And exactly which mental illnesses might benefit from psychedelic therapies? Psychopharmacologist Dr. Roger McIntyre of the University Health Network and Dr. Ishrat Husain, a psychiatrist at the Centre for Addiction and Mental Health, discuss the latest scientific developments for psilocybin, MDMA, ketamine and more. Episode 84 webpage. LINKS  Learn more about Dr. Roger McIntyre's company, Braxia Scientific, his Canadian Rapid Treatment Center of Excellence and the rest of his publications here. Here's Dr. McIntyre's webpage at U of T.  Check out Mindset Pharma Inc, where Dr. Ishrat Husain is scientific advisor. See Dr. Husain's scientific publications here. Here's Dr. Husain's webpage at CAMH.  The New England Journal of Medicine study on psilocybin. The Nature Medicine study on MDMA and PTSD. Read up on these psychedelics and wellness trials happening now: Psilocybin clinical trial for treatment-resistant depression Braxia Ketamine clinical trial to treat bipolar depression - Braxia Psilocybin-based compound clinical trial for MSP-1014 to treat mood disorders - Mindset  MDMA clinical trial to treat PTSD (phase 3) - Numinus. Learn about earlier psychedelics studies at the trailblazing John Hopkins Centre for Psychedelic & Consciousness Research, where research on psilocybin began more than 20 years ago.  Read some books that spurred today's hype around psychedelics: How to Change Your Mind by Michael Pollan A Really Good Day by Ayelet Waldman   INSIGHTS  We use the term “psychedelics” a lot in this episode. But what does that word mean, and which drugs fall into that category? Dr. Husain explains that the term is Greek in origin and means “mind manifesting.” He calls them “very potent substances” that can “cause very profound hallucinatory experiences, which can be very powerful, but at the same time, for some people, can be quite distressing.” Dr. Roger McIntyre considers in the psychedelic category such drugs as lysergic acid diethylamide (LSD) and psilocybin (the active ingredient in so-called “magic mushrooms”), as well as dimethyltryptamine, ayahuasca, mescaline, MDMA (known as “ecstasy” or “molly”), and ketamine. [07:20] Canada legalized marijuana for both recreational and medical use in October 2018, and now anyone of legal age can access many different types of marijuana, as long as it's less than or equal to 30 grams of dried cannabis. Dr. Ishrat Husain says, “With cannabis, a lot of the research wasn't completed before it was extended to medicinal use. And I hope the same thing doesn't happen with psychedelics, I think that it would be really important for us to do the robust research before it's translated into medicinal use.” The powerful nature of these drugs means that their administration needs to come with medical supervision from experts trained in psychedelic treatments. [08:21] Both Dr. Husain and Dr. McIntyre discourage recreational use of psychedelics. They also discourage microdosing of LSD and other psychedelics for self-administered therapeutic purposes.  “I do cringe…  when I hear about people taking micro- and macrodosing for whatever medical problem,” says Dr. McIntyre, “We just don't have the evidence that that works and it's safe.” Similarly, Dr. Husain says, “we don't know what the risks are… I mean, these aren't risk free drugs...they do come with adverse effects that can cause, for instance, anxiety, it can cause dissociation, which means sort of like a break from reality, as well.” Specifically about microdosing, Dr. Husain says, “there is no study that confirms the mental health benefits of microdosing psychedelics at this point. In fact, studies that have looked at recreational users have shown that microdosing psychedelics are no better than taking a placebo.” [10:21] To minimize the risk that psychedelics are legalized before the medical and scientific implications are known, as well as minimize the risk of a backlash similar to what psychedelics experienced in the ‘70s, Dr. McIntyre believes it'll be necessary for experts from many different fields to work together. “If you engage the medical establishment, you engage the political establishment, the legal establishment, the regulatory environment, and have all players at the table saying, can we find a line of sight here? How can we do this safely and appropriately? We've got to do this with [a] multilateral partnership.” [12:43] The interest that society and the media have taken in psychedelics recently is exciting for those studying them, says Dr. Roger McIntyre. “We don't get enough hype in psychiatry,” he says. “So I welcome the hype, I welcome the hope. We need hope for people who are affected by PTSD and depression and so on…” The attention, Dr. McIntyre says, has also helped attract funding for research studies. Still, Dr. Husain warns that we shouldn't let the hype lead the way. “There's so much that we don't know yet,” Dr. Husain says. “We need to do the work before we can say that they're even useful as a treatment option,” he says. [13:35] Scientists are still learning what, exactly, psychedelics do to our brains. According to Dr. Husain, we know that psilocybin, the active compound in magic mushrooms, does at least two different things. It stimulates the receptors that create serotonin, a brain chemical responsible for improved mood, Dr. Husain explains. “Another thing that it's shown to do is, reset the brain. There's a network in the brain called the default mode network, and when we're in our own internal world, thinking about things or wondering how other people view us, that network in the brain is very, very active. And it's thought that psilocybin comes in and disrupts that network, so that we start fresh.” [16:40] Where is the future of psychedelics going? Both our experts think there's much more study, and many more therapeutic uses, ahead. “We are entering the first inning of a baseball game,” says Dr. Roger McIntyre. “my dream in the ninth inning of this baseball game, is that we have a cure for these horrible illnesses and we can reduce suicide… we can get people better, get people better fast, and not just sweep symptoms under the rug, but can actually cure the illness.” Dr. Ishrat Husain is also hopeful that the research will clarify exactly how psychedelics work, so that we can use them as efficiently and safely as possible. “It would be fantastic if we're able to show that, yes, these medications are effective, and we understand why they're effective.” [18:39]

Guest host Arlene Bynon speaks with Roger McIntyre, a Professor of Psychiatry and Pharmacology at the University of Toronto & Head of the Mood Disorders Pharmacology Unit at the University Health Network. With it being International Overdose Awareness Day, Alex and Roger discuss how the ever-growing opoid crisis has progressed throughout the pandemic, who is being effected the worse, and why street drugs are not only getting stronger, but a lot more dangerous. Let's get talking See omnystudio.com/listener for privacy information.

As much as 60–80% of doctor visits are related to stress. No pressure, but in this episode, we'll learn about how chronic stress can lead to long-term illness, how we can recognize the important symptoms, and what we can do to let off some steam. We're exploring the impact of stress – not just on our mental health, but on our physical health, too.  Joining us to provide their expertise and insights are Dr. Roger McIntyre, mood disorders expert and Professor of Psychiatry and Pharmacology at the University of Toronto, and Theresa Nguyen, Chief Program Officer and Vice President of Research and Innovation with Mental Health America.The opinions expressed are the opinions of the individuals recorded and not the opinions of Viatris.Mental Health America: mhanational.orgIn the Open Podcast: https://www.mhanational.org/podcast

Ann Rohmer talks with Dr. Roger McIntyre, a professor of Psychiatry & Pharmacology at the University of Toronto. As we approach the post-pandemic world, do we need to re-learn our social skills? Do we shake hands? Is it okay to ask “have you been vaccinated?” When will social norms return? How do we re-emerge from isolation? Tina Cortese tells us about a new survey from the Ontario Medical Association about what Ontarians want their healthcare system to look like – especially after the pandemic highlighted the deficiencies in our hospitals and long-term care homes Jim Lang speaks with Wayne Emmerson – York Region Chair and CEO about the province's plan to move ahead with a fourth subway station at Clark Avenue Tina Cortese returns with the United Way's Social Capital report and how community, trust and social networks are particularly essential especially in hard times. Ann Rohmer closes the show with a discussion with Vita Nachtscheim – she created and built a global cosmetics company but now wants to create an age-inclusive movement that recognizes beauty through all ages; she is authoring a blog and wants women to contribute

Dr. Roger McIntyre, a psychiatrist, joins the podcast to discuss topics in psychiatry, mood disorders and more in this PV Roundup specialist spotlight podcast.

Dr. Roger McIntyre, a psychiatrist, joins the podcast to discuss topics in psychiatry, mood disorders and more in this PV Roundup specialist spotlight podcast.


It may seem like Bipolar Disorder is reaching epidemic proportions. That's not exactly true. It's just that until now we have been misdiagnosing it. Our teens seem to be especially susceptible to this life changing mental health illness. One of the world's foremost experts on Bipolar, Dr. Roger McIntyre, discusses the most credible research on it's possible causes and the latest treatments.

In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.  Presenters:Roger McIntyre, MD, FRCPCProfessor of Psychiatry and PharmacologyDepartment of Psychiatry/PharmacologyUniversity of TorontoHead, Mood Disorders Psychopharmacology UnitDepartment of PsychiatryToronto, CanadaJoseph Goldberg, MDClinical Professor of PsychiatryDepartment of PsychiatryIcahn School of Medicine at Mount SinaiNew York, New YorkContent based on an online CME program supported by an educational grant from Neurocrine Biosciences.Link to full program:https://bit.ly/2RM8hfM 

What unique risk factors surround the COVID-19 pandemic and potential heightened risk of suicide? What populations have been most vulnerable to mental health consequences, substance use disorders, suicidal ideation, and self-harm during the pandemic and why? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on the suicide risk and prevalence during this challenging time. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

See omnystudio.com/listener for privacy information.

What is the evidence that obesity leaves one vulnerable to bipolar disorder? Which of your patients with bipolar disorder would you refer for TMS and what has been the outcome in your experience? Have you seen development of mania with this treatment? What impact or changes have you seen in your bipolar patients who have suffered with COVID? In this Bonus episode of the NEI Podcast, Dr. Roger McIntyre addresses these questions and more unanswered questions from the Q&A session for our NEI Synapse Half-Day on The Cutting-Edge of Mood Disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders. To register for Synapse Half-Days go to: https://www.neiglobal.com/Synapse/SynOverview/tabid/468/Default.aspx

What do clinicians need to know about the pharmacokinetics of ketamine, especially when it comes to drug-drug interactions? What is the abuse potential for ketamine and for esketamine? What are some ways that clinicians can mitigate the risk of abuse? At this time, what is the consensus, in comparing the efficacy of ketamine and esketamine for treatment resistant depression? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on their recent publication in the American Journal of Psychiatry. To access the article click on the link: https://pubmed.ncbi.nlm.nih.gov/33726522/ Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

Guest Host Arlene Bynon speaks with Roger McIntyre, Prof. of Psychiatry and Pharmacology and UofT. Head of Mood Disorders Psychopharmacology Unit at the University Health Network. They talk about the becoming more commonplace term "Brain Fog." What it really means, who it affects, and how to clear the fog.  Let's Get Talking See omnystudio.com/listener for privacy information.

Guest Host Arlene Bynon speaks with Roger McIntyre, a Prof. of Psychiatry and Pharmacology at the University of Toronto,  Head of Mood Disorders Psychopharmacology Unit at the University Health Network. They discuss the rise of protests and rallies during this 3rd wave, and how the human brain is wired to handle the stress. See omnystudio.com/listener for privacy information.

Feeling tired? Unmotivated? You might be experiencing pandemic burnout. We discuss the impact of long-term stress on our brains and memory with Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, and Dr. Natasha Rajah, professor in the department of psychiatry at McGill University and the Douglas Research Centre in Montreal.

COVID-19 continues to impact our mental health and as we head towards winter that of course leads to many people suffering from Seasonal Affective Disorder. The Director of the Scientific Advisory Board of the Depression and Bipolar Support Alliance from Chicago Dr. Roger McIntyre discusses mental health concerns and how people can cope.

Among the many social and economic problems the Covid-19 pandemic has caused is the strain on mental health and, with that, an increase in the possibility of suicides. According to a recent study, we should expect an increase in the number of suicides brought on by financial troubles, stress from isolation and overall heightened fear. FOX's Trey Yingst speaks with Dr. Roger McIntyre, professor at the University of Toronto and the author of a new study that has some grim predictions about suicide in the wake of coronavirus, but also has some answers.     Learn more about your ad choices. Visit megaphone.fm/adchoices

Among the many social and economic problems the Covid-19 pandemic has caused is the strain on mental health and, with that, an increase in the possibility of suicides. According to a recent study, we should expect an increase in the number of suicides brought on by financial troubles, stress from isolation and overall heightened fear. FOX's Trey Yingst speaks with Dr. Roger McIntyre, professor at the University of Toronto and the author of a new study that has some grim predictions about suicide in the wake of coronavirus, but also has some answers.    

Today's Show : CEO of Engineered Tax Services & Financial Expert, Julio Gonzalez calls in, Real Estate Mogul and Popular Commentator, David Zere calls in, Famous Doctor, Roger McIntyre calls in, Candidate For Supreme Court Of Georgia, Hal Moroz calls in, U.S. Congressional Candidate From Virginia, Andrew Knaggs calls in, U.S. Congressional Candidate From Arizona, Josh Barnett calls in, Crime Expert & Best Selling Author, Carlo Cavazutti calls in, Political Activist and Columnist, Chris Carter calls in, President Trump Threatens to Punish Michigan for Mailing Absentee Ballot Applications to Voters, At least 30K Mail-In Votes Counted After Election Day in Wisconsin, New Black Panther Party Launches Boycott of ‘Chinese Merchants' to Protest Racism, Acting DNI Grenell Declassifies Susan Rice Email on January 2017 WH Meeting, Man Who Filmed Ahmaud Arbery's Death Charged with Murder, Vatican ties to China, Senate Committee Authorizes Subpoena in Hunter Biden-Burisma Investigation, Andrew Cuomo Blames ‘Trump's CDC' for Nursing Home Deaths , Multiple Universities Refuse to Cooperate with Federal Investigations into Ties to China, Joe Biden's Attack on Don Jr. Backfires as Hunter's Baggage Retakes Center Stage, Trump Administration Awards Contract to Shift Drug Manufacturing to the United States, Hillary Clinton Raises $2 Million for Joe Biden's Campaign Operation, Susan Rice's Declassified January 2017 Email Cites No Wrongdoing by Flynn, Supreme Court Blocks House Democrats from Mueller Grand Jury Material, Kamala Harris Submits Resolution Condemning ‘Wuhan Virus' as ‘Anti-Asian', Coronavirus Forces China to Lock Down over 100 Million People, Karl Rove Advising Trump's Campaign & Michigan AG Rages at Trump for Not Wearing Mask.

Cloth masks, another possible drug helping patients, Great American Buy Local Day, and how the cast of the 2011 film Contagion is helping spread information about COVID-19.Plus an interview on boosting your immune system with Dr. Christine Horner, one of the country's leading authorities on integrative and preventative health.And we'll hear part 2 of an interview Dr. Roger McIntyre, the Professor of Psychiatry and Pharmacology at the University of Toronto and CEO of AltMed about loneliness and isolation during COVID 19 quarantines - you can catch the first part of our talk in Monday's episode.For questions or to submit a topic or tip, email covid19daily@radiomd.com.

Coronavirus could be seasonal, how the virus is affecting animals, and what exactly is a fever?Plus an interview on pregnancies and deliveries with Avery Fisher, Certified Nurse Midwife with AFA OBGYN and Emerson Hospital.We'll also an extended interview hear from Dr. Roger McIntyre, the Professor of Psychiatry and Pharmacology at the University of Toronto and the CEO of AltMed. He'll talk to us about loneliness, which he says was a public health concern even before we were all asked to stay home, For questions or to submit a topic or tip, email covid19daily@radiomd.com.

Roger McIntyre, M.D., from Toronto,, explains the new and better understanding of cognitive changes during depressions.

Guest: Roger McIntyre, MD Host: Leslie P. Lundt, MD Substance abuse, obesity and bipolar disorder are major public health problems. They frequently co-occur, but what is the relationship between substance abuse and obesity in bipolar disorder? Dr. Roger McIntyre, associate professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada, joins host Dr. Leslie Lundt to discuss his surprising research findings.

Host: Leslie P. Lundt, MD Guest: Roger McIntyre, MD It is reported that up to a fifth of bipolar disorder patients will commit suicide, yet there are few studies looking at clinical risk factors in this population. What is the latest research? Host Dr. Leslie Lundt welcomes Dr. Roger McIntyre, associate professor of psychiatry and pharmacology at the University of Toronto School of Medicine, to discuss his latest research investigating childhood abuse with adult bipolar suicide rates.